Literature DB >> 7509138

The mechanism of action of FK-506 and cyclosporin A.

G Wiederrecht1, E Lam, S Hung, M Martin, N Sigal.   

Abstract

FK-506 and cyclosporin A (CsA) are potent immunosuppressive agents used clinically to prevent tissue rejection. Interest in the development of more effective immunosuppressive drugs has led to an intense effort toward understanding their biochemical mechanism of action with the result that these compounds have now become powerful tools used in deciphering the signal transduction events in T lymphocyte activation. Although chemically unrelated, FK-506 and CsA exert nearly identical biological effects in cells by inhibiting the same subset of early calcium-associated events involved in lymphokine expression, apoptosis, and degranulation. FK-506 binds to a family of intracellular receptors termed the FK-506 binding proteins (FKBPs). CsA binds to another family of intracellular receptors, the cyclophilins (Cyps), distinct from the FKBPs. The similarities between the mechanisms of action of CsA and FK-506 converge upon the calcium- and calmodulin-dependent serine-threonine protein phosphatase calcineurin (CaN). Both the FKBP/FK-506 complex and the Cyp/CsA complex can bind to calcineurin, thereby inhibiting its phosphatase activity. Calcineurin, a component of the signal transduction pathway resulting in IL-2 expression, catalyzes critical dephosphorylation events required for early lymphokine gene transcription.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7509138     DOI: 10.1111/j.1749-6632.1993.tb17137.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  69 in total

1.  A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling.

Authors:  M L Boytim; P Lilly; K Drouvalakis; S C Lyu; R Jung; A M Krensky; C Clayberger
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 2.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

3.  Ulcerative colitis: current treatment strategies and future prospects.

Authors:  Sagar Garud; Mark A Peppercorn
Journal:  Therap Adv Gastroenterol       Date:  2009-03       Impact factor: 4.409

Review 4.  Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients.

Authors:  Takanori Sasaki; Wataru Nakamura; Shigeko Inokuma; Erika Matsubara
Journal:  Clin Rheumatol       Date:  2015-02-03       Impact factor: 2.980

Review 5.  Probing T-cell signal transduction pathways with the immunosuppressive drugs, FK-506 and rapamycin.

Authors:  J J Siekierka
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

Review 6.  Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?

Authors:  R O Williams
Journal:  Springer Semin Immunopathol       Date:  1998

7.  The efficacy and safety of tacrolimus in rheumatoid arthritis.

Authors:  Shouma Dutta; Yasmeen Ahmad
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-12       Impact factor: 5.346

8.  Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats.

Authors:  Atsushi Yamauchi; Ryozo Oishi; Yasufumi Kataoka
Journal:  Cell Mol Neurobiol       Date:  2004-10       Impact factor: 5.046

9.  Leishmania major parasites express cyclophilin isoforms with an unusual interaction with calcineurin.

Authors:  C Rascher; A Pahl; A Pecht; K Brune; W Solbach; H Bang
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

10.  Calcineurin involvement in the regulation of high-threshold Ca2+ channels in NG108-15 (rodent neuroblastoma x glioma hybrid) cells.

Authors:  E A Lukyanetz; T P Piper; T S Sihra
Journal:  J Physiol       Date:  1998-07-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.